These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies. Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479 [TBL] [Abstract][Full Text] [Related]
4. Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview. Panchal K; Sahoo RK; Gupta U; Chaurasiya A Int Immunopharmacol; 2021 Jun; 95():107508. PubMed ID: 33725635 [TBL] [Abstract][Full Text] [Related]
5. [Advances in immunotherapy of pancreatic ductal adenocarcinoma]. Yang JQ; Wei T; Chen YW; Bai XL; Liang TB Zhonghua Wai Ke Za Zhi; 2017 May; 55(5):396-400. PubMed ID: 28464583 [TBL] [Abstract][Full Text] [Related]
6. CD137 agonist-based combination immunotherapy enhances activated, effector memory T cells and prolongs survival in pancreatic adenocarcinoma. Muth ST; Saung MT; Blair AB; Henderson MG; Thomas DL; Zheng L Cancer Lett; 2021 Feb; 499():99-108. PubMed ID: 33271264 [TBL] [Abstract][Full Text] [Related]
7. Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas: The Cancer Immunity Cycle. Kieler M; Unseld M; Bianconi D; Prager G Pancreas; 2018 Feb; 47(2):142-157. PubMed ID: 29346215 [TBL] [Abstract][Full Text] [Related]
8. CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma. Raj D; Nikolaidi M; Garces I; Lorizio D; Castro NM; Caiafa SG; Moore K; Brown NF; Kocher HM; Duan X; Nelson BH; Lemoine NR; Marshall JF Clin Cancer Res; 2021 Mar; 27(5):1538-1552. PubMed ID: 33479048 [TBL] [Abstract][Full Text] [Related]
9. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. Raj D; Yang MH; Rodgers D; Hampton EN; Begum J; Mustafa A; Lorizio D; Garces I; Propper D; Kench JG; Kocher HM; Young TS; Aicher A; Heeschen C Gut; 2019 Jun; 68(6):1052-1064. PubMed ID: 30121627 [TBL] [Abstract][Full Text] [Related]
10. Prediction of anti-CD25 and 5-FU treatments efficacy for pancreatic cancer using a mathematical model. Shafiekhani S; Dehghanbanadaki H; Fatemi AS; Rahbar S; Hadjati J; Jafari AH BMC Cancer; 2021 Nov; 21(1):1226. PubMed ID: 34781899 [TBL] [Abstract][Full Text] [Related]
11. Modeling pancreatic cancer in mice for experimental therapeutics. Mallya K; Gautam SK; Aithal A; Batra SK; Jain M Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188554. PubMed ID: 33945847 [TBL] [Abstract][Full Text] [Related]
12. [Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects]. Ye C; Zheng L; Yuan CH Zhonghua Wai Ke Za Zhi; 2019 Jan; 57(1):10-15. PubMed ID: 30612387 [TBL] [Abstract][Full Text] [Related]
13. The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications. Liu X; Xu J; Zhang B; Liu J; Liang C; Meng Q; Hua J; Yu X; Shi S Mol Cancer; 2019 Dec; 18(1):184. PubMed ID: 31831007 [TBL] [Abstract][Full Text] [Related]
14. Research progress and design optimization of CAR-T therapy for pancreatic ductal adenocarcinoma. Li T; Li H; Li S; Xu S; Zhang W; Gao H; Xu H; Wu C; Wang W; Yu X; Liu L Cancer Med; 2019 Sep; 8(11):5223-5231. PubMed ID: 31339230 [TBL] [Abstract][Full Text] [Related]
15. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer. Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281 [TBL] [Abstract][Full Text] [Related]
16. Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Silvestris N; Brunetti O; Vasile E; Cellini F; Cataldo I; Pusceddu V; Cattaneo M; Partelli S; Scartozzi M; Aprile G; Casadei Gardini A; Morganti AG; Valentini V; Scarpa A; Falconi M; Calabrese A; Lorusso V; Reni M; Cascinu S Crit Rev Oncol Hematol; 2017 Mar; 111():152-165. PubMed ID: 28259290 [TBL] [Abstract][Full Text] [Related]
17. Perspectives in the treatment of pancreatic adenocarcinoma. Cid-Arregui A; Juarez V World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356 [TBL] [Abstract][Full Text] [Related]
18. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Liudahl SM; Betts CB; Sivagnanam S; Morales-Oyarvide V; da Silva A; Yuan C; Hwang S; Grossblatt-Wait A; Leis KR; Larson W; Lavoie MB; Robinson P; Dias Costa A; Väyrynen SA; Clancy TE; Rubinson DA; Link J; Keith D; Horton W; Tempero MA; Vonderheide RH; Jaffee EM; Sheppard B; Goecks J; Sears RC; Park BS; Mori M; Nowak JA; Wolpin BM; Coussens LM Cancer Discov; 2021 Aug; 11(8):2014-2031. PubMed ID: 33727309 [TBL] [Abstract][Full Text] [Related]
19. Delivering a Double Whammy: Targeting Stroma to Improve Immunotherapy Outcomes in Pancreatic Ductal Adenocarcinoma. Lavania S Gastroenterology; 2022 Nov; 163(5):1159-1161. PubMed ID: 36067817 [No Abstract] [Full Text] [Related]
20. Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma. Blair AB; Zheng L Chin Clin Oncol; 2017 Jun; 6(3):31. PubMed ID: 28705008 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]